Sunnyvale, California-based Ceribell said the NTAP covers up to $2,171 per eligible Medicare patient case utilizing the technology. The NTAP goes into effect on Oct. 1, 2026.
Ceribell’s system utilizes point-of-care electroencephalography (EEG), analyzing segments and notifying clinicians when patterns associated with delirium are detected. It supports more timely, reliable evaluation and continuous monitoring. The system can now support continuous seizure, electrographic status epilepticus (ESE) and delirium monitoring at the bedside.
FDA clearance, picked up last December, made the platform the first and only FDA-cleared delirium screening and monitoring device.
Ceribell said the addition of the NTAP expands coverage options for point-of-care EEG for critically ill patients. It builds on the company’s existing FDA-cleared technology for detecting seizures and electrographic status epilepticus (ESE). The company’s unified platform integrates both seizure and delirium monitoring into a single system.
According to Ceribell, its comprehensive diagnostic insights help providers manage co-occurring brain risks without requiring separate devices.
“We believe that CMS’ NTAP decision underscores the profound clinical necessity and transformative value of our point-of-care technology for critically ill patients,” said Jane Chao, co-founder and CEO of Ceribell. “The add-on payment will help facilitate widespread commercial access to this vital innovation for a highly vulnerable patient population. This marks a pivotal milestone in our strategic mission to establish EEG as an essential new vital sign for better brain care.”
